XOFLX® is Minaris Advanced Therapies’ lentiviral packaging and producer cell line platform developed to address the scalability, cost, and consistency challenges associated with lentiviral vector (LVV) manufacturing. The platform uses stable cell lines with genomically integrated lentiviral components, reducing or eliminating the need for multiple plasmids and simplifying or removing transfection steps. This approach helps … Continued